Alimera Sciences (STU:ASZ1) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences 3-Year EBITDA Growth Rate?

Alimera Sciences's EBITDA per Share for the three months ended in Mar. 2024 was €0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alimera Sciences was 72.00% per year. The lowest was -33.50% per year. And the median was 34.10% per year.

Competitive Comparison of Alimera Sciences's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alimera Sciences's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's 3-Year EBITDA Growth Rate falls into.

Alimera Sciences 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Alimera Sciences (STU:ASZ1) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Alimera Sciences 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (STU:ASZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ALIM:USA ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines